Company news
Quanterix Corporation (NASDAQ:QTRX) news
Every Quanterix Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Quanterix Names Jim Gute Chief Commercial Officer
August 10, 2026
Quanterix Releases Financial Results for the Second Quarter of 2026
August 10, 2026
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
August 4, 2026
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Mult...
July 14, 2026
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
June 9, 2026
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
June 4, 2026
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase ...
May 18, 2026
Quanterix Announces Planned Transition of Chief Financial Officer
May 12, 2026
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
May 6, 2026
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
April 24, 2026
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
April 17, 2026
Quanterix Debuts Content Innovation Engine at AACR 2026
April 15, 2026
Quanterix Corporation Announces Date of 2026 Annual Meeting
March 27, 2026
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
March 2, 2026
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
March 2, 2026
Quanterix to Participate in Upcoming Investor Conferences
February 26, 2026
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
February 20, 2026
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
February 3, 2026
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling
January 21, 2026
Quanterix Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
January 19, 2026
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
January 8, 2026
Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
December 22, 2025
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
November 20, 2025
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
November 17, 2025
Quanterix Releases Financial Results for the Third Quarter of 2025
November 10, 2025
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
November 3, 2025
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
August 21, 2025
Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference
August 11, 2025
Quanterix Releases Financial Results for the Second Quarter of 2025
August 7, 2025
Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025
August 4, 2025
Quanterix Announces Cooperation Agreement with Kent Lake Capital
August 4, 2025
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
July 28, 2025
Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the B...
July 8, 2025
Quanterix Expands Reach with IVD and Large Reference Labs
June 23, 2025
Quanterix to Present at Goldman Sachs Global Healthcare Conference
June 6, 2025
Quanterix Releases Financial Results for the First Quarter of 2025
May 12, 2025
Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025
May 5, 2025
Kent Lake Issues Statement on Quanterix’s Blatant Disregard for Will of Shareholders
April 30, 2025
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
April 29, 2025
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
April 1, 2025
Quanterix Releases Financial Results for the Fourth Quarter of 2024
March 17, 2025
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
March 13, 2025
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
March 3, 2025
Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024
November 12, 2024
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
October 2, 2024
Quanterix Announces Commercialization of p-Tau 217 Test Kit
September 30, 2024
Quanterix Releases Financial Results for the Second Quarter of 2024
August 8, 2024